The median levels in exhaled NO were lower in women with HER2‐positive tumors (2.64 ± 0.72, Figure 3E) and in situ BC (2.55 ± 0.43, Figure 3F), although the differences were not significant. This evidence concerns the gene ERBB2 and breast cancer.